Reduction of plasma cholesterol levels and induction of hepatic LDL receptor by cerivastatin sodium (CAS 143201-11-0, BAY w 6228), a new inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase, in dogs

Cardiovascular Drugs and Therapy

Volumn 11, Issue 4, 1997, Pages 567-574

  Yasunobu, Yuji ^a   Hayashi, Kozo ^a   Shingu, Tetsuji ^a   Nomura, Katsuhiko ^a   Ohkura, Yoshifumi ^a   Tanaka, Kouichi ^a   Kuga, Yoshio ^a   Nomura, Syu Ichi ^a   Ohtani, Harumi ^a   Nishimura, Takaharu ^b   Matsuura, Hideo ^a   Kajiyama, Goro ^a  

^a HIROSHIMA UNIV SCHOOL OF MEDICINE   (Japan)

^b Environ Biol Life Sci Res C   (Japan)

Author keywords

3 hydroxy 3 methylglutaryl coenzyme A reductase inhibitor; BAY w6228; Cerivastatin sodium; LDL receptor; Plasma cholesterol concentration

Indexed keywords

CERIVASTATIN; CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN RECEPTOR; MESSENGER RNA; PRAVASTATIN; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ANIMAL EXPERIMENT; ARTICLE; CELL STRAIN HEPG2; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DOG; DOSE RESPONSE; DRUG EFFECT; DRUG MECHANISM; HUMAN; HUMAN CELL; MALE; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RECEPTOR BINDING; RECEPTOR UPREGULATION; SCATCHARD PLOT;

ANIMALS; BLOTTING, NORTHERN; CELL LINE; CHOLESTEROL; DOGS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LIPOPROTEINS, LDL; LIVER; MALE; MICROSOMES, LIVER; PYRIDINES; RECEPTORS, LDL; RNA, MESSENGER;

EID: 9844246988     PISSN: 09203206     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1007731603663     Document Type: Article

References (29)

1. Martin MJ, Hulley SB, Browner WS, et al. Serum cholesterol, blood pressure, and mortality: Implications from a cohort of 361662 men. Lancet 1986;933-939.
2. Grundy SM. Cholesterol and coronary heart disease. JAMA 1986;256:2849-2858.
3. Wilson PWF, Castelli WP, Kannel WB. Coronary risk prediction in adults (The Framingham Heart Study). Am J Cardiol 1987;59:91G-94G.
4. Castelli WP, Garrison RJ, Wilson PWF, et al. Incidence of coronary heart disease and lipoprotein cholesterol levels. The Framingham Study. JAMA 1986;256:2835-2838.
5. Stamler J, Wentworth D, Neaton JD. Is relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded? Findings in 356222 primary screenees of the multiple Risk Factor Intervention Trial (MRFIT). JAMA 1986;56:2823-2828.
6. Lipid Research Clinics Program. The Lipid Research Clinics Coronary Primary Prevention Trial Results. II. The relationship of reduction in incidence of coronary heart disease to cholesterol lowering. JAMA 1984;251:365-374.
7. Kane JP, Malloy MJ, Ports TA, et al. Regression of coronary atherosclerosis during treatment of familial hypercholesterolemia with combined drug regimens, JAMA 1990; 264:3007-3012.
8. Watts GF, Lewis B, Brunt JNH, et al. Effects of coronary artery disease of lipid-lowering diet, or diet plus cholestyramine, in the St Thomas' Atherosclerosis Regression Study (STARS). Lancet 1992;339:563-569.
9. Manninen V, Huttunen JK, Heinonen OP, et al. Relation between baseline lipid and lipoprotein values and the incidence of coronary disease in the Helsinki Heart Study. Am J Cardiol 1989;63:42H-47H.
10. The Pravastatin Multinational Study Group for Cardiac Risk Patients. Effects of pravastatin in patients with serum total cholesterol levels from 5.2 to 7.8 mmol/liter (200 to 300 mg/dl) plus two additional atherosclerotic risk factors. Am J Cardiol 1993;72:1031-1037.
11. Pedersen TR, Kjekshus J, Berg K, et al. Randomised trial of cholesterol lowering in 444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (43). Lancet 1994;344:1383-1389.
12. Oliver MF, de Feyter PJ, Lubsen J, et al. Effect of simvastatin on coronary atheroma: The Multicentre Anti-atheroma Study (MAAS). Lancet 1994;344:633-638.
13. Brown BG, Adams WA, Albers JA, et al. Quantitative arteriograph in coronary intervention trials; rationale, study design, and lipid response in the university of Washington familial atherosclerosis treatment study (FATS). In Glagov S, Newman WP III, Schaffer SA (eds). Pathobiology of the Human Atherosclerotic Plaque. New York: Springer Verlag, 1990:536-650.
14. Shepherd J, Cobbe SM, Ford I. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995;333:1301-1307.
15. Pitt B, Mancini GBJ, Eillis SG, et al. Pravastatin limitation of atherosclerosis in coronary arteries (PLAC I) (abstr). J Am Coll Cardiol 1994;special issue:131.
16. Crouse JR III, Byington RP, Bond MG. Pravastatin, lipids, and atherosclerosis in the carotid arteries (FLAG II). Am J Cardiol 1995;74:455-459.
17. Jukem JW, Bruschke AVJ, van Boven AJ, et al. Effects of lipid lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels. The Regression Growth Evaluation Statin Study (REGRESS). Circulation 1995;91:2528-2540.
18. Reihner E, Rudling M, Stahlberg D, et al. Influence of pravastatin, a specific inhibitor of HMG-CoA reductase, on hepatic metabolism of cholesterol. N Engl J Med 1990;323:224-228.
19. Ma PST, Gil G, Sudhof TC, et al. Mevinolin, an inhibitor of cholesterol synthesis, induces mRNA for low density lipoprotein receptor in livers of hamsters and rabbits, froc Nail Acad Sci USA 1989;83:8370-8374.
20. Schneider WJ. The low density lipoprotein receptor. Biochim Biophys Acta 1989;988:303-317.
21. Bischoff H, Petzinna D. BAY w6228: A new generation HMG-CoA reductase inhibitor. II. Inhibition of cholesterol synthesis in rats and dogs (abstr). XI Int Symp Drugs Affecting Lipid Metabolism (Florence) 1992;69.
22. Hayashi K, Koide K, Hirata Y, et al. Metabolic changes in lipids of rat plasma hepatocytes induced by 17 α-ethynylestrandiol treatment. Biochim Biophys Acta 1986;879:140148.
23. Burstein M, Scholnick HR, Morfin R. Rapid method for the isolation of lipoproteins from human serum by precipitation with polyanions. J Lipid Res 1970;11:583-695.
24. McFarlane AS. Effect of trace-labelling of proteins with iodine. Nature 1958;182:53.
25. Hayashi K, Hirata Y, Kurushima H, et al. Effect of dietary hydrogenated corn oil (trans-octadecenoate rich oil) on plasma and hepatic cholesterol metabolism in the hamster. Atherosclerosis 1993;99:97-106.
26. Hayashi K, Nimph J, Schneider WJ, et al. Chicken oocytes and fibroblasts express different apoprotein-B-specific receptors. J Biol Chem 1989;264:3131-3139.
27. Chomczynski P, Sacchi N, Single-Step Method of RNA isolation by guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 1987;162:156-159.
28. Scatchard G. The attractions of proteins for small molecules and ions. Ann N Y Acad Sci 1949;51:660-672.
29. Thomas G, Paglia R. BAY w6228: A new generation HMGCoA reductase inhibitor. lll, Serum cholesterol lowering effects in dogs (abstr). XI Int Symp Drugs Affecting Lipid Metabolism (Florence) 1992;70.